Versartis intends to price initial public offering of its common stock

Morgan Stanley and Citigroup will be the bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Feb. 18 - Versartis, Inc. will conduct an initial public offering of its common stock with a greenshoe option, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Morgan Stanley and Citigroup are the joint bookrunning managers. Cowen and Co. is the lead manager, and Canaccord Genuity is the co-manager.

Proceeds will be used for the phase 3 clinical trial of VRS-317, capital, capital expenditures and other general corporate purposes.

The endocrine-focused biopharmaceutical company is based in Redwood City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.